Arive

Quick links to important sections

Arive

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arive

Property Description
Active Ingredient Aripiprazole
Pharmacological Class Atypical Antipsychotic (Second-Generation Antipsychotic)
Forms Tablets, Oral Solution, Injectable Suspension
Origin Synthetic (Quinolinone Derivative)
Common Purpose Stabilization of thought processes and mood

What is Arive and How is it Classified?

Arive is a prescription-only medication with the active pharmaceutical ingredient (API) Aripiprazole, which is classified as an atypical antipsychotic, also referred to as a second-generation antipsychotic (SGA). Aripiprazole is a modern, single-ingredient treatment primarily intended to help patients achieve and maintain stability in the management of severe mood and mental health conditions.

The classification of Arive as an atypical antipsychotic is based on its differential interaction profile with neuroreceptors compared to older treatments. This profile indicates that the medication supports consistent symptom management and is clinically recognized for its broad-spectrum stabilizing properties. The drug is a complex, synthetic compound that ultimately aims to restore equilibrium within the central nervous system, promoting clearer thinking and improved behavioral control.


Aripiprazole: Composition, Chemical Origin, and Forms

The pharmacological activity of Arive is entirely dependent on its active ingredient, Aripiprazole, which is a chemically synthesized quinolinone derivative. This single-ingredient product is available in multiple pharmaceutical preparations to suit different clinical requirements and patient preferences, distinguishing its use beyond a single oral format.

Arive is most commonly delivered via the oral route in the form of conventional tablets, an oral solution (liquid), or orally disintegrating tablets. This versatility in dosage forms is a key feature, allowing for therapeutic options that range from routine oral dosing to continuous administration via intramuscular injection, including extended-release injectable suspension forms.


What is the General Purpose of Arive?

The general purpose of Arive is to achieve essential neurotransmitter balancing within the brain, particularly by modulating the activity of dopamine and serotonin to regulate mood and perception. Aripiprazole functions uniquely as a dopamine system stabilizer, meaning it acts as a partial agonist to gently modulate receptor activity, rather than fully blocking it as older agents do.

This stabilizing mechanism is crucial because it helps to normalize chemical signaling where the activity is disordered. By helping to balance these critical chemical messengers, the medication supports the patient in regaining equilibrium over disordered thought processes and mitigating severe emotional states. This stabilizing action provides a foundation for consistent, long-term symptom management.

Regulatory References

  1. Aripiprazole - StatPearls - NCBI Bookshelf
  2. Aripiprazole: MedlinePlus Drug Information

What side effects are possible with Arive?

Official Adverse Reactions and Safety Profile

The safety profile of Arive (Aripiprazole) is officially documented by government regulatory authorities, detailing potential adverse reactions and specific constraints. These reactions are classified by frequency of occurrence observed in clinical studies and post-marketing surveillance.

Frequency Classification

The most frequently reported effects are classified as Very Common (ge 1 in 10 people), which include Akathisia (inner restlessness), Insomnia, and Headache. Effects classified as Common (ge 1 in 100 people) span multiple systems and include Somnolence, Restlessness, Tremor, Nausea, Vomiting, Constipation, Dizziness, Weight gain, and Blurred vision.

System-Organ Classes and Serious Reactions

Adverse reactions are organized into System-Organ Classes (SOC), primarily involving Nervous System Disorders (e.g., Akathisia, Tremor) and Psychiatric Disorders (e.g., Insomnia, Restlessness). The official labeling highlights several rare but serious adverse reactions associated with the atypical antipsychotic class, including Neuroleptic Malignant Syndrome (NMS) and the potential for Tardive Dyskinesia.

Additionally, the medication is associated with a risk of significant Metabolic Changes, such as hyperglycemia and weight gain, as documented in official prescribing information.

Population-Specific Safety Statements

Regulatory documents include specific safety constraints for certain patient groups. Aripiprazole is associated with an increased risk of mortality and cerebrovascular adverse reactions in older adults with dementia-related psychosis, an unapproved use. Furthermore, an increased risk of suicidal thoughts and behaviors is noted in children, adolescents, and young adults when using this medication as adjunctive therapy for Major Depressive Disorder, particularly at the start of treatment or following a dose change.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Arive overdose documents manifestations that commonly affect the central and motor systems. Overdose presentations reported in regulatory sources include pronounced somnolence (drowsiness/lethargy), tremor, vomiting, and tachycardia (elevated heart rate). The most serious outcomes documented include seizures, coma, hypotension, and cardiac dysrhythmia, such as potential QTC interval prolongation. The severe, life-threatening symptom complex of Neuroleptic Malignant Syndrome (NMS) is also a documented risk associated with exposure.

Regulatory guidance mandates that immediate medical attention must be sought, requiring contact with an Emergency Room or Poison Control Center at once when an overdose is suspected or symptoms are present. This urgent action is required because no specific antidote is known for Aripiprazole overdose, and haemodialysis is unlikely to be useful due to the drug’s high protein binding. Management is officially defined as symptomatic and supportive therapy, which may include the use of activated charcoal to reduce absorption and continuous cardiac monitoring. Pediatric patients may exhibit a distinct presentation of profound and long-lasting lethargy and increased Extrapyramidal Symptoms (EPS).

Therapeutic Uses of Arive

Arive is commonly used across conditions characterized by periods of heightened symptoms to provide symptomatic relief and assists with maintaining functional stability. The core therapeutic domains are generally considered relevant in clinical settings that involve acute or disruptive symptom patterns.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns for the management of Schizophrenia, the treatment of acute manic and mixed episodes in Bipolar I Disorder, adjunctive therapy for Major Depressive Disorder, and for addressing irritability associated with Autistic Disorder and tics in Tourette's Disorder.

“The medication is considered relevant for easing symptoms that become more disruptive during flare-ups.”

Symptom Stabilization and Support

Arive plays a role in managing distressing manifestations such as hallucinations, delusions, and severe suspicion (psychosis), and is applied in addressing the intense symptoms of mood instability and behavioral dyscontrol. It contributes to improved comfort during periods of heightened symptoms, which assists with maintaining functional stability when symptoms become more noticeable.


Quick Fact: Managing Psychotic and Severe Mood Symptoms Arive may be part of symptomatic management for symptom clusters that may become intense or disruptive, applied in addressing the symptoms of psychosis and acute mania to help patients cope more steadily.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Arive (Aripiprazole) eligibility is strictly defined by regulatory documents, outlining which populations are approved for use and which are contraindicated or restricted.

Populations That Must Not Use Arive (Contraindications)

Use of Arive is contraindicated in patients with a known hypersensitivity reaction to Aripiprazole or any component of the medication. Additionally, it is not approved and contraindicated for use in elderly patients with dementia-related psychosis due to an officially documented increased risk of death.

Age-Group and Condition Eligibility

The medicine is generally approved for adults for all labeled indications. Pediatric use has specific age limits: approval extends to adolescents ge 13 years old for Schizophrenia and Bipolar I Disorder, and to children ge 6 years old for Irritability associated with Autistic Disorder and Tourette's Disorder. Use is not recommended for children under 6 years of age.

Physiological and Organ Restrictions

  • Pregnancy: Use is restricted, particularly in the third trimester, as it may cause newborn symptoms.
  • Lactation: Aripiprazole is excreted in human milk, and its use is not recommended while breastfeeding.
  • Organ Function: Use requires caution in patients with severe hepatic impairment due to insufficient data. Eligibility is conditional for patients who are CYP2D6 poor metabolizers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aripiprazole's official interaction profile is defined by two primary documented pathways: pharmacokinetic modification and pharmacodynamic additive effects. Pharmacokinetic interactions involve the CYP3 A4 and CYP2 D6 enzyme systems, which metabolize the medicine. Strong inhibitors of these enzymes increase Aripiprazole's systemic exposure, while strong inducers decrease it, often requiring dosage constraints when used concomitantly for longer than 14 days.

Key Documented Interaction Outcomes

Interaction Type Interacting Substance Category Resulting Formal Outcome
Pharmacokinetic ( PK) Strong CYP Inhibitors (e.g., Fluoxetine, Itraconazole) Increased systemic exposure
Pharmacokinetic ( PK) Strong CYP Inducers (e.g., Carbamazepine, Rifampin) Decreased systemic exposure
Pharmacodynamic ( PD) Other CNS Depressants (e.g., Alcohol, Benzodiazepines) Increased intensity of sedation and enhanced orthostatic hypotension risk

Certain long-acting injectable formulations carry restrictions against the co-administration of both a strong CYP2 D6 inhibitor and a strong CYP3 A4 inhibitor. A population-specific constraint exists for CYP2 D6 Poor Metabolizers ( PMs), who inherently experience higher systemic exposure, necessitating interaction-based dosing adjustments. Regarding non-medicinal substances, the official labeling notes that combining the medicine with alcohol is documented to increase nervous system side effects. Herbal products such as St. John's Wort are also noted as potential enzyme inducers that may reduce the medicine's effectiveness.

Mechanism of Action

Arive's pharmacological action is defined by its ability to act as a Dopamine System Stabilizer, which is achieved through a unique, multi-receptor profile that modulates activity within the central nervous system's (CNS) monoamine systems. The mechanism is exclusively focused on influencing neuroreceptor activity and the resulting physiological cascades.

Dopamine System Stabilization via Partial Agonism

Arive's primary action involves partial agonism at the high-affinity Dopamine mathbfD2 receptor (mathbfD2R). This unique mechanistic interaction is functionally selective: where dopamine signaling is excessive (hyperactive), the drug acts as a net antagonist to dampen the signal; conversely, where signaling is deficient (hypoactive), it acts as a net agonist to provide a minimal signal. This dynamic modulation of mathbfD2 receptor tone influences neurotransmission dynamics and contributes to a modulated physiological state within the brain.

Complementary Serotonin Receptor Modulation

The drug also engages the Serotonergic System by interacting with multiple mathbf5-HT receptor subtypes, notably acting as a partial agonist at the mathbf5-HT1A receptor and an antagonist at the mathbf5-HT2A receptor. The mathbf5-HT2A antagonism is a key mechanistic step that contributes to the overall modulatory effect by influencing the flow of dopamine in critical brain regions. This complementary modulation contributes to the resulting modulation of neurotransmitter dynamics that is characteristic of the drug's physiological effect profile.

Dosage and Administration Information

Aripiprazole (Arive) is administered through two main official routes: oral for daily consumption and intramuscular (IM) injection for both acute management and long-term maintenance. The oral forms are available across a range of strengths up to 30 mg and may be taken once daily without regard to the timing of meals.

Official dosing regimens establish specific starting and maintenance dose ranges. For adult Schizophrenia treatment, the typical starting dose is 10 mg or 15 mg once daily. Dose adjustments are standardized and should not be made more frequently than every two weeks to allow the active compound to reach consistent concentrations in the body, with a ceiling of 30 mg as the maximum daily dose for most indications.

For maintenance treatment, long-acting injectable (LAI) suspensions are administered on a fixed calendar schedule, such as once monthly or once every two months, by a healthcare professional deep into the muscle. When initiating this long-acting therapy, official instructions mandate a 14-day overlap period where oral Aripiprazole must be taken concurrently to ensure continuous activity.

Specific usage rules apply to particular patient groups. For example, patients identified as poor metabolizers of the CYP2D6 enzyme are officially recommended to receive half of the usual oral dose. However, no routine dose adjustment is required for individuals with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Arive (Aripiprazole)

The clinical understanding of Arive is based on formal research, primarily Randomized Controlled Trials (RCTs), which are a high standard of evidence often used in clinical review. These trials are conducted under controlled conditions and compare the medication against an inactive substance (placebo) to observe patterns related to symptom outcomes. The following summary describes what these studies explored, what patterns were observed, and what remains uncertain, based on reviews by regulatory authorities.


Evidence for Use in Schizophrenia

Research for Schizophrenia includes short-term and long-term studies, often lasting four to six weeks for acute treatment or several months for maintenance. These trials focused on measuring changes in symptom intensity using standardized research tools like the PANSS. Data show patterns related to both short-term symptom changes and differences in the proportion of individuals who maintained stability compared to those receiving a placebo. However, the evidence is limited regarding extensive, multi-year follow-up for measures of functional recovery.


Evidence for Use in Bipolar I Disorder and MDD (Adjunctive)

For Bipolar I Disorder, Arive was evaluated in short-term RCTs for acute manic or mixed episodes, exploring changes in symptom intensity using the Young Mania Rating Scale (YMRS). Findings indicate patterns related to the prevention of new manic episodes in maintenance research scenarios. For Major Depressive Disorder, research explored adding Arive to existing antidepressant regimens in adults who had previously reported an incomplete response. Trials reported differences in the mean change in MADRS scores compared to adding placebo.


Evidence in Specific Populations and Research Gaps

Research also includes studies in pediatric patients for managing specific behavioral manifestations like irritability associated with Autistic Disorder and tics associated with Tourette's Disorder. These studies primarily focus on short-term outcomes. Data for older adults with certain neurocognitive conditions or individuals with significant medical comorbidities remain insufficient. Furthermore, research describes group patterns, which do not predict individual results, and comparative evidence against every other available treatment in every indication is lacking.

Frequently Asked Questions (FAQ)

Common questions about Arive (FAQ)

Q: What is Arive used for exactly, besides the main thing?

According to official regulatory documents, Aripiprazole (Arive) is approved for several conditions. This includes the treatment of Schizophrenia, acute Manic and Mixed episodes of Bipolar I Disorder, and as an add-on treatment for Major Depressive Disorder (MDD) in adults. It is also approved for managing Irritability associated with Autistic Disorder and Tourette's Disorder in specific pediatric populations.

Q: Is Arive a new type of medicine or has it been around for a while?

Aripiprazole (Arive) is classified as a second-generation antipsychotic. Official records indicate the active ingredient was first approved by the U.S. Food and Drug Administration (FDA) in November 2002, confirming its use for several years.

Q: Is Arive considered a strong medication?

Official information classifies Aripiprazole as an atypical antipsychotic. It is further described as a Dopamine System Stabilizer because it works uniquely to modulate (balance) the activity of dopamine and serotonin in the brain, rather than fully blocking these chemicals.

Q: How long does it usually take for Arive to start working?

Official prescribing information states that the body needs time to build up consistent levels of the active compound. Dosage adjustments are therefore generally not made before two weeks of use. This period allows the medicine to reach consistent concentrations, which is a factor considered when assessing treatment effects.

Q: If I miss a dose of Arive, what generally happens?

Official patient information generally advises that if a dose of the oral form is missed, instructions often advise taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the medicine is typically resumed at the regular time. This guidance helps maintain consistent medicine levels in the body.

Q: Can Arive affect my ability to drive or use machinery?

Regulatory documents state that Aripiprazole can cause side effects such as drowsiness, dizziness, and changes in motor skills. For this reason, patients should avoid driving, operating heavy machinery, or engaging in other hazardous activities until they are certain how Aripiprazole affects them.

Q: Is Arive addictive or habit-forming?

Aripiprazole is not officially listed as being addictive. However, official warnings describe a risk of developing unusual and uncontrollable compulsive urges in some patients. These urges can include pathological gambling, compulsive eating, shopping, or excessive sexual urges.

Q: Are the side effects of Arive usually permanent or temporary?

Most common side effects have been observed to lessen or resolve following dose adjustment or discontinuation of the medication. However, one serious but rare adverse reaction, Tardive Dyskinesia (uncontrolled body movements), is officially noted as possibly being permanent, even after the medication is discontinued.

Q: Do I need any special tests or monitoring while using Arive?

Official prescribing information recommends certain monitoring while using this medication. This includes monitoring for potential metabolic changes, such as checking blood sugar and fat (lipid) levels, as well as tracking weight gain. For patients with a history of low white blood cell counts, complete blood cell counts (CBC) may also be performed.

Q: Is Arive a high-risk medication?

Like other medications in its class, Aripiprazole carries several important regulatory warnings. This includes a boxed warning regarding an increased risk of death in older adults with dementia-related psychosis, and an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults when used for Major Depressive Disorder.

Q: What happens if I stop taking Arive suddenly?

Sudden cessation of Aripiprazole may increase the likelihood of withdrawal symptoms or a return of original symptoms (relapse). Official guidance advises against stopping suddenly and suggests that a gradual dose reduction or tapering is typically recommended.

Q: Is there a generic version of Arive available?

Yes. Aripiprazole is the active ingredient in Arive and is available under the brand name as well as in generic versions.

Q: Are there certain foods or drinks I should avoid while using Arive?

Aripiprazole oral formulations can be taken once daily without regard to the timing of meals. However, official labeling warns against combining the medicine with alcohol and advises that the herbal product St. John's Wort may reduce the medicine's effectiveness.

Q: Can Arive be used by older adults?

The use of Aripiprazole is contraindicated (not allowed) in elderly patients with dementia-related psychosis, as documented by a boxed warning due to an increased risk of death and cerebrovascular adverse reactions. Official information defines this restriction, and eligibility for other approved uses requires professional assessment.

Q: Is Arive suitable for people with [common long-term condition, e.g., high blood pressure]?

Caution is advised for individuals with known cardiovascular or cerebrovascular disease. Official warnings note that the medicine is associated with a risk of orthostatic hypotension (a drop in blood pressure when standing). Monitoring for metabolic changes, such as high blood sugar and weight gain, is also recommended.

Q: Is Arive safe to use during pregnancy, according to official information?

The use of Aripiprazole is restricted, particularly during the third trimester of pregnancy, as it may cause symptoms in the newborn. Furthermore, Aripiprazole is excreted in human milk, and its use is officially not recommended while breastfeeding.

Q: What is the general success rate mentioned in the clinical trials for Arive?

Official documents summarizing clinical trials state that studies indicated a difference in effectiveness compared to a placebo (inactive substance) in improving the severity of symptoms for the approved conditions. This finding was based on measurements using standardized rating scales such as the PANSS, YMRS, and MADRS.

Q: Does Arive require a gradual increase or decrease in use?

Yes. Dosage increases are generally adjusted gradually, over a minimum period of two weeks. Official guidance also advises against stopping the medication suddenly, and a gradual dose reduction or tapering is typically recommended when discontinuing Aripiprazole.

Q: Are there specific times of the day Arive is recommended to be taken?

Regulatory documents instruct that the oral forms of Aripiprazole are generally taken once daily. While the time of day is not explicitly specified as mandatory, taking the dose at the same time each day is recommended to help maintain a consistent level of medicine in the body.

Q: What is the shelf life of Arive?

The Aripiprazole Oral Solution has a specific regulatory instruction that it must be discarded six months after the date of first opening. For the tablet forms, the expiration date that defines the shelf life is printed directly on the container label.

Q: Does Arive contain any ingredients that cause allergic reactions?

Use is contraindicated in patients with a known hypersensitivity reaction to Aripiprazole or any of its components. Additionally, official labeling notes that some forms, such as the orally disintegrating tablet, contain phenylalanine, which is an important consideration for patients with the metabolic condition phenylketonuria (PKU).

How should Arive be stored and disposed of?

How to Store and Dispose of Arive?

The storage and disposal instructions for Arive (Aripiprazole) must align strictly with official regulatory labeling to ensure product stability and safety.

Storage Conditions

Arive tablets and solution must be stored at controlled room temperature, specifically between 59 F and 86 F (15 C and 30 C). The medication must be kept in its original, tightly closed container and protected from moisture. The Aripiprazole Oral Solution has the mandatory restriction to not freeze.

All forms of Arive must be stored out of the sight and reach of children.

Stability and Disposal

The Oral Solution should be discarded six months after the date of first opening. Unused or expired medication must be disposed of according to local environmental regulations. Regulatory guidance advises against flushing the medicine down a toilet and suggests mixing it with an unappealing substance, placing it in a sealed bag, and discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arive found in:

A-Z Index: